Breaking News, Financial News

Financial Report: Charles River Laboratories

RMS segment sales were up, while PCS segment sales declined

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories 4Q Revenues: $291.0 million (+3%) 4Q Earnings: $27.1 million (loss of $342.4 million 4Q10) FY Revenues: $1.1 billion (+1%) FY Earnings: $115.5 million (loss of $334.1 million FY10) Comments: Sales for the Research Models and Services (RMS) segment were $182.4 million in 4Q11 (+8%), and $705.4 million for the year (+6%). Sales from the Preclinical Services (PCS) segment in the quarter were $108.5 million (-4%), due to shorter term, less complex studies, as well as ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters